Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBIT: 2019-2024

Historic EBIT for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$102.7 million.

  • Foghorn Therapeutics' EBIT rose 22.43% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year increase of 16.92%. This contributed to the annual value of -$102.7 million for FY2024, which is 4.84% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported EBIT of -$102.7 million as of FY2024, which was up 4.84% from -$107.9 million recorded in FY2023.
  • Foghorn Therapeutics' EBIT's 5-year high stood at -$68.5 million during FY2020, with a 5-year trough of -$117.1 million in FY2022.
  • Over the past 3 years, Foghorn Therapeutics' median EBIT value was -$107.9 million (recorded in 2023), while the average stood at -$109.2 million.
  • In the last 5 years, Foghorn Therapeutics' EBIT crashed by 46.99% in 2021 and then rose by 7.88% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' EBIT (Yearly) stood at -$68.5 million in 2020, then plummeted by 46.99% to -$100.7 million in 2021, then decreased by 16.28% to -$117.1 million in 2022, then rose by 7.88% to -$107.9 million in 2023, then climbed by 4.84% to -$102.7 million in 2024.